Screening people with liver scarring in primary care
Part of Digestive system clinical trials.
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver scarring risk from either non-alcohol fatty liver disease or alcohol-related disease
- You meet at least one risk definition, such as high alcohol intake, type 2 diabetes, or certain metabolic issues (like high blood pressure, abnormal cholesterol, or high ferritin)
- You agree to have a blood sample taken at a local participating lab
- You are able to give written informed consent (or have the legal ability to consent)
- You are not already under specialized follow-up for a chronic liver condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
This study checks people who are at higher risk for liver scarring by using noninvasive tests. If those tests suggest significant scarring, the study may consider further testing, but not everyone will need a biopsy.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.